Nitescu Nicoletta, Grimberg Elisabeth, Ricksten Sven-Erik, Marcussen Niels, Guron Gregor
Department of Anaesthesiology and Intensive Care, Institute of Clinical Sciences, The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
Nephrol Dial Transplant. 2007 Aug;22(8):2149-55. doi: 10.1093/ndt/gfm158. Epub 2007 Apr 3.
Renal ischaemia-reperfusion (IR) is associated with activation of the coagulation system and inflammation within the kidney. The aim of the present study was to examine the effects of selective thrombin inhibition with melagatran on kidney morphology and function in rats subjected to renal IR.
Sprague-Dawley rats underwent renal IR (35 min of bilateral renal arterial clamping), or sham surgery. Treatment groups were: (i) IR-Saline, (ii) IR-Melagatran, (iii) Sham-Saline, and (iv) Sham-Melagatran. Twenty minutes prior to renal IR, the rats were administered a bolus dose of saline vehicle or melagatran [0.5 mumol/kg, subcutaneously (s.c.)] followed by a continuous infusion throughout (0.08 micromol/kg/h, s.c.). Forty-eight hours after IR, renal function was assessed in anaesthetized animals and kidney histology was analysed semi-quantitatively.
Rats in group IR-Saline showed an approximate 85% reduction in glomerular filtration rate, 5-fold increases in fractional urinary excretion rates of sodium, potassium and water, and marked renal histological abnormalities, compared with sham (P < 0.05). Renal histopathological changes in the cortex and outer medulla were characterized by tubular necrosis and atrophy, tubular cast formation and interstitial inflammation. In addition, there was significant vascular congestion in the inner stripe of the outer medullary zone. Melagatran treatment had no significant effects on any of the abnormalities in kidney morphology or function in rats subjected to renal IR. Plasma melagatran concentrations were within a range known to exert significant antithrombotic effects, throughout the study period.
Thrombin inhibition with melagatran did not ameliorate abnormalities in kidney morphology or function 48 h after renal IR. These results indicate that melagatran is not renoprotective in rats subjected to renal IR.
肾缺血再灌注(IR)与凝血系统激活及肾脏内炎症反应相关。本研究旨在探讨用美拉加群选择性抑制凝血酶对肾IR大鼠肾脏形态和功能的影响。
将Sprague-Dawley大鼠进行肾IR(双侧肾动脉夹闭35分钟)或假手术。治疗组包括:(i)IR-生理盐水组,(ii)IR-美拉加群组,(iii)假手术-生理盐水组,和(iv)假手术-美拉加群组。在肾IR前20分钟,给大鼠静脉推注生理盐水或美拉加群[0.5 μmol/kg,皮下注射(s.c.)],随后持续输注(0.08 μmol/kg/h,s.c.)。IR后48小时,在麻醉动物中评估肾功能,并对肾脏组织学进行半定量分析。
与假手术组相比,IR-生理盐水组大鼠的肾小球滤过率降低约85%,钠、钾和水的尿排泄分数率增加5倍,且有明显的肾脏组织学异常(P<0.05)。皮质和外髓质的肾脏组织病理学变化特征为肾小管坏死和萎缩、管型形成和间质炎症。此外,外髓质区内带存在明显的血管充血。美拉加群治疗对肾IR大鼠的肾脏形态或功能异常均无显著影响。在整个研究期间,血浆美拉加群浓度处于已知可发挥显著抗血栓作用的范围内。
美拉加群抑制凝血酶并不能改善肾IR后48小时的肾脏形态或功能异常。这些结果表明,美拉加群对肾IR大鼠无肾脏保护作用。